HOUSTON–(BUSINESS WIRE)–XCath Robotics, a medical device company advancing endovascular surgical robotics, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Iris Surgical Robotic System for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. The FDA’s Breakthrough Devices Program is designed to support the development of medical devices that have the potential to provide more effective treatment f
Other News
Kestra Names Daniel Finney Vice President of Research & Development
KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company’s executive leadership team. “Research and development is central to advancing our mission and expanding the role of wearable protection for at-risk patients during critical periods of recovery,” said Brian Webster, President and Chief Executive Officer. “The Cardiac Recovery System® platform was designed from the outset to evolve. Dan’s hands-on role in developing the ASSURE® WCD, together with his technical depth, product experience, and demonstrated leadership, positions him to guide our next phase of innovation and extend the platform’s value for patients and providers.” Mr. Finney succeeds Phillip D. Foshee, Jr., who led Kestra’s research and development organization from 2016 until his recent retirement. During his nearly decade-long tenure, Mr. Foshee spearheaded the development of the ASSURE WCD and helped establish the technical foundation on which Kestra continues to build. The appointment comes as Kestra advances an integrated product strategy across the Cardiac Recovery System platform. Building on its extensible architecture, Mr. Finney will lead initiatives spanning internal research and development, strategic partnerships, and the application of AI, with priorities informed by clinical evidence and real-world insights from patients and clinicians. This evidence base includes findings from the ASSURE Clinical Evaluation Post-Approval Study (ACE-PAS), the largest prospective real-world study of wearable cardioverter defibrillators conducted to date. “It has been incredibly rewarding to be part of the team that brought the ASSURE WCD from concept to market and to see firsthand its impact on patients and its role in expanding the wearable defibrillator category,” said Mr. Finney. “That experience gives me confidence in the strength and potential of the Cardiac Recovery System platform. I’m genuinely excited about our vision and roadmap, and I look forward to leading this team as we advance the next generation of wearable cardiac protection.” Mr. Finney has more than 20 years of experience in Class III medical device development, engineering management, and project management. Most recently, he served as Kestra’s Senior Director of New Product Development, leading engineering teams and product development initiatives. Before joining Kestra, he held product development roles with Stryker, Physio-Control, and Medtronic. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of April 22, 2026. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2026 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 14, 2026, and in other periodic reports filed by Kestra with the SEC. These filings are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmati
Implicity secures $40M growth equity funding to scale its AI-driven cardiac monitoring platform globally
The round is led by growth fund IRIS alongside Five Arrows. Funding will fuel Implicity’s next phase of growth in the US through local commercial hires, build on its established leadership across Europe, and accelerate further AI investment. Implicity already serves over 250 medical centers and monitors 120,000+ patients daily […]
Q’Apel Medical Announces U.S. Launch of the Lynx™ Aspiration Catheter System
Company expands its neurovascular portfolio and broadens its offering for stroke intervention Engineered performance supports aspiration in complex anatomy Marks the second product to feature its proprietary Q’Apel Laser Cut Tube (QLCT™) technology FREMONT, Calif., Sept. 9, 2026…
Medicana Uses Robot-Assisted Technology to Perform Heart Surgery Through Small Ports
Medicana Health Group’s Prof. Suat Büket, MD explains how selected bypass and heart-valve procedures can be completed without dividing the breastbone while maintaining the same surgical objective Photo: Robotic heart surgery at Medicana Health Group via FL Comms ISTANBUL, Sept. 09, 2026 (GLOBE NEWSWIRE) — For selected heart patients, complex surgery can now be performed through several small openings between the ribs rather than by dividing the breastbone. Robot-assisted cardiac surgery combines a surgeon-controlled console with high-definition three-dimensional imaging, tremor filtration and highly articulated instruments, offering a minimally invasive route to procedures that have traditionally required a full sternotomy. Prof. Suat Büket, MD, a cardiovascular surgeon at Medicana Health Group, said the most important point is often misunderstood: the robot does not perform the operation independently. “The surgeon remains in control at every stage. The system translates the surgeon’s hand movements into precise movements inside the chest. Its value lies in giving us a magnified three-dimensional view and a range of motion that is difficult to achieve with conventional instruments through a small opening,” said Prof. Büket. Photo: Prof. Suat Büket, MD via FL Comms Several small ports instead of a divided breastbone In conventional open-heart surgery, access to the heart often requires a midline incision and division of the sternum. The bone is then rejoined at the end of the operation and must heal over the following weeks, during which patients may face movement restrictions. Wound and bone-healing complications can be particularly challenging for patients with certain risk factors. In robot-assisted cardiac surgery, the surgical team can access the chest through three or four ports between the ribs, each approximately one centimetre, depending on the planned operation. A camera and the robotic instruments are introduced through these openings. The surgeon operates from a console in the operating theatre while the bedside team supports the procedure. Technology expands the surgeon’s view and reach The system’s high-definition camera provides a three-dimensional, magnified view of the operative field. Wristed instruments can bend and rotate beyond the range of the human hand, while computer-assisted tremor filtration supports steady movement. These features are designed to help the surgeon work precisely in confined anatomical spaces; they do not replace clinical judgement or the surgical team. The robot is a surgical instrument — not an autonomous decision-maker. Patient selection, operative planning and every surgical movement remain the responsibility of the trained clinical team. The surgical objective does not change Prof. Büket stressed that a minimally invasive approach should not mean a reduced operation. When robot-assisted surgery is clinically appropriate, the aim is to complete the same planned cardiac repair or revascularisation that would otherwise be performed through an open approach. “If the plan is to perform bypass grafting or repair or replace a heart valve, the objective remains the same. The difference is the route we use to reach the heart. A smaller incision must never mean an incomplete procedure,” he said. Recovery benefits depend on the right patient Avoiding sternotomy may reduce the burden of bone healing and allow some patients to return to everyday movement sooner. Smaller incisions may also reduce wound-related concerns and can offer cosmetic and psychosocial benefits. However, not every patient is a candidate. The decision depends on the planned procedure, anatomy, previous operations, vascular access and the findings of pre-operative tests. “Robotic cardiac surgery is not automatically the best option simply because the incisions are smaller,” Prof. Büket said. “The safest and most effective approach is selected after a complete assessment. Technology adds value when it is matched to the right patient, the right procedure and an experienced team.” From precision tools to connected operating rooms Robot-assisted surgery also points toward a more connected future for operating theatres. Research into remote surgical support and telesurgery continues, but current practice still depends on a trained surgical team, specialist infrastructure and direct clinical oversight. For Prof. Büket, the immediate priority is not distance but precision: using the technology available today to reduce surgical trauma without compromising the completeness or safety of the operation. About Medicana Health Group Founded in 1992, Medicana Health Group is one of Türkiye’s leading privately owned healthcare providers, operating 19 hospitals in Türkiye, the United Kingdom, and Bosnia and Herzegovina. Serving more than 5 million patients annually, including a significant international patient base, Medicana delivers multidisciplinary care across a broad range of specialties with a strong focus on clinical excellence and patient-centered service. In addition to healthcare, the Group invests in education through Medicana Education Group and Fenerbahçe University. With approximately 15,000 employees, Medicana continues to expand its international footprint while advancing sustainability through renewable energy investments and supporting Turkish sports through long-term health sponsorships. Media contact Uğur AlkaparGlobal Media Relations DirectorFL Communicationsugur@flcommunications.co.uk This press release is intended for general informational purposes. Treatment decisions must be made by qualified clinicians following an individual patient assessment. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b10f86c-bc1f-41a5-a99e-3a5afb79b174 https://www.globenewswire.com/NewsRoom/AttachmentNg/92e8455e-008d-4a4a-9c60-1b85de881324
Emboline Receives U.S. FDA 510(k) Clearance for Emboliner® Embolic Protection System
Clearance brings full cerebral and systemic embolic protection to patients undergoing transcatheter aortic valve replacement (TAVR) SANTA CRUZ, Calif., Sept. 9, 2026 /PRNewswire/ — Emboline, Inc., a medical technology company developing next-generation embolic protection technology,…
egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data
The upgrade accelerates a health system’s capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways ALISO VIEJO, Calif., Sept. 8, 2026 /PRNewswire/ — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage…
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Strong clinical evidence demonstrates the device’s high rates of safety and effectiveness…
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf


